Changes in circulating forms of anti-Muüllerian ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Changes in circulating forms of anti-Muüllerian hormone and androgens in women with and without PCOS: a systematic longitudinal study throughout pregnancy
Auteur(s) :
Peigne, Maeliss [Auteur]
Hôpital Jeanne de Flandres
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Hôpital Jean Verdier [AP-HP]
Simon, Victor [Auteur]
Hôpital Jeanne de Flandre [Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Pigny, Pascal [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Mimouni, Nour El Houda [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Martin, C. [Auteur]
Service de Biostatistiques [CHRU Lille]
Dewailly, Didier [Auteur]
Hôpital Jeanne de Flandre [Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Jonard-Catteau, Sophie [Auteur]
Hôpital Jeanne de Flandre [Lille]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Giacobini, Paolo [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Hôpital Jeanne de Flandres
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Hôpital Jean Verdier [AP-HP]
Simon, Victor [Auteur]
Hôpital Jeanne de Flandre [Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Pigny, Pascal [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Mimouni, Nour El Houda [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Martin, C. [Auteur]
Service de Biostatistiques [CHRU Lille]
Dewailly, Didier [Auteur]
Hôpital Jeanne de Flandre [Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Jonard-Catteau, Sophie [Auteur]
Hôpital Jeanne de Flandre [Lille]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Giacobini, Paolo [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Titre de la revue :
Human Reproduction
Nom court de la revue :
Hum Reprod
Numéro :
38
Pagination :
938–950
Éditeur :
Oxford University Press (OUP)
Date de publication :
2023-03-15
ISSN :
1460-2350
Mot(s)-clé(s) en anglais :
PCOS
AMH
pregnancy
AMH molecular forms
androgens
AMH
pregnancy
AMH molecular forms
androgens
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
STUDY QUESTION
What are the changes in serum concentration of total and cleaved anti-Muüllerian hormone (AMH) molecular forms and of androgens before and throughout pregnancy in women with and without polycystic ovary ...
Lire la suite >STUDY QUESTION What are the changes in serum concentration of total and cleaved anti-Muüllerian hormone (AMH) molecular forms and of androgens before and throughout pregnancy in women with and without polycystic ovary syndrome (PCOS) in a longitudinal follow-up investigation? SUMMARY ANSWER Serum levels of total and cleaved AMH are higher from preconception to the third trimester of pregnancy in women with PCOS as compared to controls, whereas testosterone and androstenedione levels are higher in women with PCOS than in control women before pregnancy and during the second and third trimester of pregnancy. WHAT IS KNOWN ALREADY Cross-sectional or partial longitudinal studies have shown higher AMH and androgen levels in pregnant women with PCOS as compared with non-PCOS women. To date, no complete longitudinal dynamic monitoring of the circulating forms of AMH and androgens from pre-conception to the third trimester of pregnancy have compared women with and without PCOS. STUDY DESIGN, SIZE, DURATION This systematic prospective quarterly longitudinal monocentric study was a comparative follow-up of 30 women with PCOS and 29 controls before and during pregnancy from April 2019 to July 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS Women aged 18–43 years with a pre-conception measurement of AMH were included during the first trimester of a singleton pregnancy. The PCOS group was defined according to the Rotterdam diagnostic criteria. The control group patients included in the study had normal ovarian reserves. Circulating total and cleaved AMH, and serum estradiol, LH, and androgen levels were measured during the first, second, and third trimester of pregnancy in all study participants. MAIN RESULTS AND THE ROLE OF CHANCE Before pregnancy, patients with PCOS had higher levels of AMH than controls. The total and cleaved AMH forms were significantly higher in women with PCOS than controls from pre-conception to the third trimester of pregnancy (all P < 0.001). Androgens (total testosterone and androstenedione) were higher in women with PCOS than controls from mid-pregnancy onwards. LIMITATIONS, REASONS FOR CAUTION Our control population was a population of infertile women with no ovarian problems but most of them had undergone ART treatments to achieve pregnancy. WIDER IMPLICATIONS OF THE FINDINGS These results strengthen the hypothesis that gestational hyperandrogenism as well as exposure to elevated AMH levels in utero could be driving forces predisposing female progeny to develop PCOS. STUDY FUNDING/COMPETING INTEREST(S) Funding was provided by INSERM, France (grant number U1172) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, ERC-2016-CoG to P.G. grant agreement n° 725149/REPRODAMH. The authors have nothing to declare. TRIAL REGISTRATION NUMBER NCT03483792Lire moins >
Lire la suite >STUDY QUESTION What are the changes in serum concentration of total and cleaved anti-Muüllerian hormone (AMH) molecular forms and of androgens before and throughout pregnancy in women with and without polycystic ovary syndrome (PCOS) in a longitudinal follow-up investigation? SUMMARY ANSWER Serum levels of total and cleaved AMH are higher from preconception to the third trimester of pregnancy in women with PCOS as compared to controls, whereas testosterone and androstenedione levels are higher in women with PCOS than in control women before pregnancy and during the second and third trimester of pregnancy. WHAT IS KNOWN ALREADY Cross-sectional or partial longitudinal studies have shown higher AMH and androgen levels in pregnant women with PCOS as compared with non-PCOS women. To date, no complete longitudinal dynamic monitoring of the circulating forms of AMH and androgens from pre-conception to the third trimester of pregnancy have compared women with and without PCOS. STUDY DESIGN, SIZE, DURATION This systematic prospective quarterly longitudinal monocentric study was a comparative follow-up of 30 women with PCOS and 29 controls before and during pregnancy from April 2019 to July 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS Women aged 18–43 years with a pre-conception measurement of AMH were included during the first trimester of a singleton pregnancy. The PCOS group was defined according to the Rotterdam diagnostic criteria. The control group patients included in the study had normal ovarian reserves. Circulating total and cleaved AMH, and serum estradiol, LH, and androgen levels were measured during the first, second, and third trimester of pregnancy in all study participants. MAIN RESULTS AND THE ROLE OF CHANCE Before pregnancy, patients with PCOS had higher levels of AMH than controls. The total and cleaved AMH forms were significantly higher in women with PCOS than controls from pre-conception to the third trimester of pregnancy (all P < 0.001). Androgens (total testosterone and androstenedione) were higher in women with PCOS than controls from mid-pregnancy onwards. LIMITATIONS, REASONS FOR CAUTION Our control population was a population of infertile women with no ovarian problems but most of them had undergone ART treatments to achieve pregnancy. WIDER IMPLICATIONS OF THE FINDINGS These results strengthen the hypothesis that gestational hyperandrogenism as well as exposure to elevated AMH levels in utero could be driving forces predisposing female progeny to develop PCOS. STUDY FUNDING/COMPETING INTEREST(S) Funding was provided by INSERM, France (grant number U1172) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, ERC-2016-CoG to P.G. grant agreement n° 725149/REPRODAMH. The authors have nothing to declare. TRIAL REGISTRATION NUMBER NCT03483792Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Projet Européen :
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Équipe(s) de recherche :
Développement et plasticité du cerveau neuro-endocrine
Date de dépôt :
2024-01-15T23:24:56Z
2024-12-04T13:38:10Z
2024-12-04T13:38:10Z
Fichiers
- dead050.pdf
- Version éditeur
- Accès libre
- Accéder au document